Synopsis: Pace Digitek updated multiple strategic initiatives, including manufacturing expansion, research investments, subsidiary restructuring, and, aimed at strengthening its position in the rapidly growing energy storage sector. The shares of this small cap...
Synopsis: The share of this company surged after Nykaa outlined a FY30 vision targeting revenue growth to Rs 43,000 crore, driven by strong Beauty, Fashion, and B2B expansion plans. The share of this company, which is a leading Indian omnichannel e-commerce retailer...
Synopsis: This company is scaling its US business through product launches, regulatory approvals, and a strong pipeline, aiming to reach USD 1 billion in revenue driven by respiratory and specialty segment expansion. The article outlines the target and capacity of the...
Synopsis: This small-cap infrastructure company has guided for FY27 revenue of Rs.3,200–3,400 crore, implying growth of up to 29 percent, backed by an executable order book of Rs.11,338 crore. The company is also expanding its BESS manufacturing capacity from 2.5 GWh...
Synopsis A leading global agrochem company slashes debt by $850 Mn, earns rating upgrades from three global agencies, and nearly quadruples its profit in a single year – all while beating every guidance metric it set. In a year marked by falling commodity...
Synopsis: Shares of this company rose about 4 percent after strong FY30 growth guidance, including 100 percent revenue growth target, higher market share plans, and robust Q4 performance across key business segments The share of this company, which is India’s leading...
Synopsis: The share of this pharmaceutical company came into focus after reporting Q4 FY26 results and outlining a plan to achieve nearly 50 percent revenue growth over the next three years. The shares of this company, which is focused heavily on R&D and novel...
Synopsis: Transmission stock shares fell 7% after Q4FY26 PAT declined 24% YoY. Despite weak quarterly results, the company reported strong FY26 growth, a robust Rs. 16,361 crore order book, and guided for 20–22% revenue growth in FY27. The shares of this company are...
Synopsis: The share of this company surged after strong 184 percent India revenue growth outlook, stable margin guidance of 18–20 percent, and expansion plans. The shares of this company, which manufactures and sells products primarily under the Carysil and luxury...
Synopsis: Akums Drugs is entering FY27 with unusually high revenue visibility. A long-term European CDMO agreement, a Zambia government supply partnership, and a ₹300 crore expansion plan are now converging at the same time. The bigger story is no longer just...
